WOBURN, Mass.–(BUSINESS WIRE)–February 26, 2019 ROMEG Therapeutics, an innovative drug development company focused on alternative formulations to better meet clinical and patient needs, today announced that the U.S. Food and Drug Administration…Original Article
You may also like
Dupixent (dupilumab) Approved in the U.S. as the First...
U.S. Food and Drug Administration Updates Camzyos...
FDA Grants Isturisa (osilodrostat) Expanded Indication...
Neurelis Announces FDA Approval for Immediate Use...
Mirum’s Livmarli Now FDA Approved in Tablet...
FDA Grants Interchangeable Designation to Yuflyma...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
